Category Archives: Hormone Receptors

SOR-C13 and Psaptides for Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to peptide SOR-C13 (Sorcimed) for the treatment of ovarian cancer. Additionally, two forms of a peptide derived from a naturally-occurring human protein (Psaptides) can force tumors to shrink significantly in an animal model of metastatic ovarian cancerContinue reading

Ibrance plus Faslodex Improves Outcomes in HR+ Breast Cancer

In a Phase 3 Paloma-III study of Pfizer’s CDK4/6 inhibitor (Ibrance – palbociclib) and an estrogen receptor antagonist (Faslodex – fulvestrant), patients receiving the combination had significantly prolonged progression-free survival than women with breast cancer who received Faslodex, alone. Continue reading

Entinostat Doesn’t Just Restore Sensitivity to Aromatase Inhibitors

Entinostat is currently in a Phase III trial in combination with Aromasin (exemestane – aromatase inhibitor that blocks the synthesis of estrogen) in patients with metastatic breast cancer who have recurred following treatment with an aromatase inhibitor. Continue reading

Targeted therapies for cancer – overview

The National Cancer Institute has a very informative, yet easy to understand overview  presented as a Q&A – Targeted Cancer Therapies. Continue reading

Genentech Acquires Seragon – Selective Estrogen Receptor Degraders for breast cancer

Roche /Genentech announced that it acquired a company called Seragon for its new class of compound – SERD (selective Estrogen Receptor Degraders).  Blocking estrogen production (aromatse inhibitors) and the binding to the estrogen receptor (tamoxifen) are mainstays of treatment for patients with ER (estrogen receptor) and PR (progesterone receptor) positive breast cancer.  However, patients relapse subsequent to treatment with these agents. Continue reading